TrialBridgeNCT07089121
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Recruiting · Phase 1, Phase 2 · Cartesian Therapeutics · registry updated 2026-07-27
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
Inclusion
- At least age 12
- definitive diagnosis of childhood-onset systemic lupus erythematous, juvenile Myasthenie gravis, juvenile dermatomyositis and AAV
- Signs and symptoms of moderate disease
- History of systemic treatment
- Parent/Guardian/Patient must be able to give written informed consent
Exclusion
- Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient;
- Abnormal PT/INR or PTT increased \> 1.5-fold or patient is on anticoagulation therapy (except in cases of elevated PTT with documented lupus anticoagulant; or in patients who have been on stable doses of anticoagulation therapy for more than 6 months of VTE diagnosis; or in patients on stable doses of anticoagulation therapy for at least 8 weeks of atrial fibrillation diagnosis; these conditions will not be exclusionary unless, in the investigator's opinion, they make participation in the study unsafe);
- ANC \< 1000 cells/microliter ;
- Hemoglobin \< 8.0 g/dL ;
- Platelets \< 50,000/mm3 (NOTE: platelet transfusions are permissible);
- ALT and/or AST with GGT ≥ 3× upper limit of normal